questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Nucléoprotéines
Protéines de liaison à l'ARN
Facteurs d'épissage des ARN
Facteurs d'épissage des ARN : Questions médicales fréquentes
Termes MeSH sélectionnés :
Randomized Controlled Trials as Topic
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Facteurs d'épissage des ARN : Questions médicales les plus fréquentes",
"headline": "Facteurs d'épissage des ARN : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Facteurs d'épissage des ARN : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-17",
"dateModified": "2025-05-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Facteurs d'épissage des ARN"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de liaison à l'ARN",
"url": "https://questionsmedicales.fr/mesh/D016601",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de liaison à l'ARN",
"code": {
"@type": "MedicalCode",
"code": "D016601",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine PTB",
"alternateName": "Polypyrimidine Tract-Binding Protein",
"url": "https://questionsmedicales.fr/mesh/D038941",
"about": {
"@type": "MedicalCondition",
"name": "Protéine PTB",
"code": {
"@type": "MedicalCode",
"code": "D038941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur d'épissage associé à PTB",
"alternateName": "PTB-Associated Splicing Factor",
"url": "https://questionsmedicales.fr/mesh/D000072670",
"about": {
"@type": "MedicalCondition",
"name": "Facteur d'épissage associé à PTB",
"code": {
"@type": "MedicalCode",
"code": "D000072670",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.282"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Petites ribonucléoprotéines nucléaires U1",
"alternateName": "Ribonucleoprotein, U1 Small Nuclear",
"url": "https://questionsmedicales.fr/mesh/D017412",
"about": {
"@type": "MedicalCondition",
"name": "Petites ribonucléoprotéines nucléaires U1",
"code": {
"@type": "MedicalCode",
"code": "D017412",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.313"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Petites ribonucléoprotéines nucléaires U2",
"alternateName": "Ribonucleoprotein, U2 Small Nuclear",
"url": "https://questionsmedicales.fr/mesh/D017413",
"about": {
"@type": "MedicalCondition",
"name": "Petites ribonucléoprotéines nucléaires U2",
"code": {
"@type": "MedicalCode",
"code": "D017413",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.344"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Petites particules nucléaires ribonucléoprotéiques U5",
"alternateName": "Ribonucleoprotein, U5 Small Nuclear",
"url": "https://questionsmedicales.fr/mesh/D017415",
"about": {
"@type": "MedicalCondition",
"name": "Petites particules nucléaires ribonucléoprotéiques U5",
"code": {
"@type": "MedicalCode",
"code": "D017415",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.375"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteurs d'épissage riches en sérine-arginine",
"alternateName": "Serine-Arginine Splicing Factors",
"url": "https://questionsmedicales.fr/mesh/D000068103",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs d'épissage riches en sérine-arginine",
"code": {
"@type": "MedicalCode",
"code": "D000068103",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur d'épissage U2AF",
"alternateName": "Splicing Factor U2AF",
"url": "https://questionsmedicales.fr/mesh/D000072668",
"about": {
"@type": "MedicalCondition",
"name": "Facteur d'épissage U2AF",
"code": {
"@type": "MedicalCode",
"code": "D000072668",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Antigène intracellulaire-1 des lymphocytes T",
"alternateName": "T-Cell Intracellular Antigen-1",
"url": "https://questionsmedicales.fr/mesh/D000074019",
"about": {
"@type": "MedicalCondition",
"name": "Antigène intracellulaire-1 des lymphocytes T",
"code": {
"@type": "MedicalCode",
"code": "D000074019",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.664.962.829.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Facteurs d'épissage des ARN",
"alternateName": "RNA Splicing Factors",
"code": {
"@type": "MedicalCode",
"code": "D000072260",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Omar Abdel-Wahab",
"url": "https://questionsmedicales.fr/author/Omar%20Abdel-Wahab",
"affiliation": {
"@type": "Organization",
"name": "Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: abdelwao@mskcc.org."
}
},
{
"@type": "Person",
"name": "Akihide Yoshimi",
"url": "https://questionsmedicales.fr/author/Akihide%20Yoshimi",
"affiliation": {
"@type": "Organization",
"name": "Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. rr2579@cumc.columbia.edu yoshimia@mskcc.org."
}
},
{
"@type": "Person",
"name": "Michael Sattler",
"url": "https://questionsmedicales.fr/author/Michael%20Sattler",
"affiliation": {
"@type": "Organization",
"name": "Helmholtz Munich, Molecular Targets and Therapeutics Center, Institute of Structural Biology, Ingolstädter Landstrasse 1, 85764, Neuherberg, Germany. michael.sattler@helmholtz-munich.de."
}
},
{
"@type": "Person",
"name": "Anke Busch",
"url": "https://questionsmedicales.fr/author/Anke%20Busch",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Biology (IMB), 55128 Mainz, Germany."
}
},
{
"@type": "Person",
"name": "Kathi Zarnack",
"url": "https://questionsmedicales.fr/author/Kathi%20Zarnack",
"affiliation": {
"@type": "Organization",
"name": "Buchmann Institute for Molecular Life Sciences (BMLS), Goethe University Frankfurt, 60438 Frankfurt am Main, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Differential effects of desvenlafaxine on hot flashes in women with breast cancer taking tamoxifen: a randomized controlled trial.",
"datePublished": "2024-07-17",
"url": "https://questionsmedicales.fr/article/39019875",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41523-024-00668-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39018686",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.intimp.2024.112673"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effectiveness of buccal administration of dexmedetomidine and ketamine combination in paediatric dental sedation: A randomized controlled clinical trial.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39011758",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ipd.13238"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mucosal Healing With Vedolizumab in Patients with Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial.",
"datePublished": "2024-07-16",
"url": "https://questionsmedicales.fr/article/39025255",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cgh.2024.06.037"
}
},
{
"@type": "ScholarlyArticle",
"name": "Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials.",
"datePublished": "2024-07-13",
"url": "https://questionsmedicales.fr/article/38961804",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/03007995.2024.2376129"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Nucléoprotéines",
"item": "https://questionsmedicales.fr/mesh/D009698"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de liaison à l'ARN",
"item": "https://questionsmedicales.fr/mesh/D016601"
},
{
"@type": "ListItem",
"position": 6,
"name": "Facteurs d'épissage des ARN",
"item": "https://questionsmedicales.fr/mesh/D000072260"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Facteurs d'épissage des ARN - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Facteurs d'épissage des ARN",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Facteurs d'épissage des ARN",
"description": "Comment diagnostiquer un trouble d'épissage ?\nQuels examens sont utilisés pour évaluer l'épissage ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux facteurs d'épissage ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles d'épissage ?",
"url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=999#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Facteurs d'épissage des ARN",
"description": "Quels sont les symptômes d'un trouble d'épissage ?\nLes troubles d'épissage peuvent-ils causer des cancers ?\nY a-t-il des symptômes neurologiques associés ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=999#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Facteurs d'épissage des ARN",
"description": "Peut-on prévenir les troubles d'épissage ?\nQuels conseils de santé peuvent aider ?\nLes tests prénataux sont-ils utiles ?\nY a-t-il des vaccins pour prévenir ces troubles ?\nComment le conseil génétique aide-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=999#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Facteurs d'épissage des ARN",
"description": "Quels traitements sont disponibles pour les troubles d'épissage ?\nLa thérapie génique est-elle efficace ?\nPeut-on utiliser des médicaments pour traiter ces troubles ?\nY a-t-il des essais cliniques en cours ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=999#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Facteurs d'épissage des ARN",
"description": "Quelles complications peuvent survenir ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=999#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Facteurs d'épissage des ARN",
"description": "Quels sont les facteurs de risque pour les troubles d'épissage ?\nL'âge est-il un facteur de risque ?\nLes facteurs environnementaux influencent-ils l'épissage ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie influence-t-il les risques ?",
"url": "https://questionsmedicales.fr/mesh/D000072260?mesh_terms=Randomized+Controlled+Trials+as+Topic&page=999#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un trouble d'épissage ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses d'ARN peuvent identifier des anomalies d'épissage."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer l'épissage ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'électrophorèse et le séquençage d'ARN sont couramment utilisés pour l'évaluation."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biopsies peuvent être nécessaires pour analyser les tissus affectés."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux facteurs d'épissage ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certains ARN peuvent servir de marqueurs pour ces facteurs."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles d'épissage ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas spécifique, mais peut aider à évaluer des complications associées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un trouble d'épissage ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, incluant fatigue, douleurs musculaires et anomalies neurologiques."
}
},
{
"@type": "Question",
"name": "Les troubles d'épissage peuvent-ils causer des cancers ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies d'épissage sont liées à divers types de cancers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques comme des convulsions peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré des anomalies d'épissage."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver progressivement, nécessitant un suivi régulier."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles d'épissage ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un dépistage génétique peut aider à identifier les risques."
}
},
{
"@type": "Question",
"name": "Quels conseils de santé peuvent aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain et éviter les toxines peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Les tests prénataux sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests prénataux peuvent détecter certaines anomalies génétiques liées à l'épissage."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir ces troubles ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles d'épissage."
}
},
{
"@type": "Question",
"name": "Comment le conseil génétique aide-t-il ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le conseil génétique informe les familles sur les risques et les options de dépistage."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles d'épissage ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la thérapie génique et des médicaments ciblés pour corriger l'épissage."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle montre des résultats prometteurs, mais son efficacité dépend du type de trouble."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des médicaments pour traiter ces troubles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent moduler l'épissage et améliorer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, plusieurs essais cliniques explorent de nouvelles approches thérapeutiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques, des cancers et des maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent gravement affecter la qualité de vie, nécessitant un soutien médical continu."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications à long terme peuvent survenir, nécessitant un suivi régulier."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être évitées par un traitement précoce et un suivi."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles d'épissage ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des mutations génétiques, des antécédents familiaux et des expositions environnementales."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles d'épissage sont plus fréquents chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils l'épissage ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines peut affecter le processus d'épissage des ARN."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire certains risques associés aux troubles d'épissage."
}
}
]
}
]
}
Hot flashes (HF) are a common adverse event of prolonged tamoxifen use in women with estrogen receptor-positive breast cancer, impacting psychiatric health and quality of life. While desvenlafaxine do...
This prospective, randomized, controlled clinical trial assessed the therapeutic effects of major ozone autohemotherapy (O...
Pain and anxiety can be considerable obstacles while treating paediatric dental patients. Moderate sedation is needed to treat uncooperative patients....
This study aimed to compare the effectiveness of buccal administration of dexmedetomidine-ketamine combination versus dexmedetomidine....
Fifty-six uncooperative children were randomly assigned into two groups: Group I received buccal dexmedetomidine (2 μg/kg) and ketamine (2 mg/kg) (DEX-KET), whereas Group II received buccal dexmedetom...
There were no significant differences in vital signs or sedation onset between the two groups. DEX-KET group showed shorter recovery time than DEX group (p < .0001). There were no statistically signif...
The combination of dexmedetomidine and ketamine delivered buccally provided a better method of delivering care to uncooperative children with more rapid recovery than dexmedetomidine....
Vedolizumab is indicated for the treatment of chronic pouchitis in the EU. We assessed whether vedolizumab induced mucosal healing (MH) and if MH was associated with clinical improvements....
EARNEST, a randomized, double-blind, placebo-controlled study, evaluated vedolizumab efficacy and safety in adults with chronic pouchitis. Centrally read endoscopic and histological evaluation was per...
Following treatment, mean (SD) number of ulcers in vedolizumab-treated patients reduced from 15.1 (16.4) to 5.0 (4.9) at W14 and 2.7 (3.2) at W34 vs placebo-treated patients with corresponding values ...
Vedolizumab induced endoscopic improvements in patients with chronic pouchitis, which was associated with improved outcomes at W34, particularly in patients achieving MH at W14....
gov number, NCT02790138....
We aimed to summarize survival data from RCTs in patients with GO adenocarcinoma; estimate and explain worst-, typical-, and best-case-scenarios of survival time; and determine if simple multiples of ...
We systematically searched RCTs of systemic therapies for GO adenocarcinoma published 2000-2022. The following key percentiles were extracted from overall survival curves: 90th (worst-case), 75th (low...
We identified 44 trials (22,447 participants). For first line chemotherapy and immunotherapy combined (CI) trials (...
We provide realistic, evidence-based prognostic information as scenarios for survival time which can inform clinical decision-making. Simple multiples of the mOS accurately estimated the percentiles f...
Using an iterative user-centered design process, our team developed a patient-centered adaptive supportive care system, PatientCareAnywhere, that provides comprehensive biopsychosocial screening and s...
This study aims to assess the usability of the new web-based PatientCareAnywhere system and examine the preliminary efficacy of PatientCareAnywhere to improve patient-reported outcomes compared with u...
For phase 1, usability testing participants included patients with cancer (n=4) and caregivers (n=7) who evaluated the software prototype and provided qualitative (eg, interviews) and quantitative (eg...
Participants were highly satisfied with the prototype and reported above-average acceptable usability, with a mean System Usability Scale score of 84.09 (SD 10.02). Qualitative data supported the over...
Overall, PatientCareAnywhere represents a user-friendly, functional, and acceptable supportive care intervention with preliminary efficacy to improve HRQOL among patients diagnosed with cancer. Future...
ClinicalTrials.gov NCT02408406; https://clinicaltrials.gov/study/NCT02408406....
The objective of this meta-analysis was to evaluate the efficacy of administering preoperative oral carbohydrates (CHO) compared to a control treatment in improving postoperative recovery outcomes for...
A meta-analysis of randomized controlled trials....
Through systematic searches in PubMed, Embase, and the Cochrane Library, randomized controlled trials focusing on preoperative oral carbohydrates for patients undergoing LC were collected. Data analys...
The meta-analysis incorporated 19 randomized studies, with a total of 1,568 participants. Meta-analysis results indicated that patients receiving CHO reported notably lower postoperative pain compared...
Preoperative oral carbohydrates may alleviate hunger and pain, and attenuate postoperative insulin resistance more effectively than either overnight fasting or placebo in patients undergoing LC....
In emergency medicine (EM), discerning patient expectations to inform patient-centered care poses unique challenges. We devised a novel questionnaire to facilitate clinicians' understanding of patient...
We conducted a multisite, randomized controlled trial. A brief questionnaire soliciting patient expectations was developed through feedback from clinicians and patients. At the beginning of their visi...
Among the 308 participants, 141 intervention and 123 control exit surveys were collected. In the primary analysis, the intervention group had 2.1 times greater odds of strongly agreeing that their cli...
While more patients reported that their expectations were addressed when the novel tool was used, no significant difference was found for conventional satisfaction measures. Future studies may examine...
Seven days of antibiotics are recommended in the setting of preterm premature rupture of membranes (PPROM) to promote latency. Azithromycin has generally replaced a seven-day course of erythromycin in...
We aim to compare the pharmacokinetics of one-time vs daily dosing of azithromycin in the setting of preterm pre-labor rupture of membranes (PPROM) STUDY DESIGN: This is a randomized clinical trial of...
The study was halted after N=6 enrolled due to lagging enrollment, with 3 in each group. The mean gestational age of enrollment was 27.1±1.7weeks in the 1g group and 31.0±1.4 weeks in the 500mg daily ...
500mg daily dosing of azithromycin maintains higher amniotic fluid concentrations, and more consistently greater than common MICs, over eight days compared to 1g once in the setting of PPROM....
To investigate the short-term effects of 3D-printed and prefabricated foot orthoses on the management of flat feet....
In this single-blinded study, 63 patients with flat feet were enrolled via convenience sampling. They were randomly assigned to the control and experimental groups, receiving prefabricated and customi...
VAS scores at week 0 for the two groups were not statistically significant (p > 0.05). At week 4, the VAS scores of the experimental group reduced significantly (p < 0.001), whereas the VAS scores of ...
Customized 3D-printed orthoses effectively reduced pain and enhanced patient satisfaction with comfort and effectiveness in 4 weeks....